CompletedEarly Phase 1

First-in-human Evaluation of [18F]CETO

Sweden20 participantsStarted 2019-09-01

Plain-language summary

Purpose of this clinical phase 1 trial was to determine if para-chloro-2-\[18F\]fluoroethyletomidate positron emission computed tomography (\[18F\]CETO-positron emission computed tomography(PET)/computed tomography(CT)) can be used in diagnostics of adrenal tumors and if the biochemical/pharmacological states conditions in humans with various illnesses, compared to healthy humans, such as the radio tracer is suitable?

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with adrenal incidentalomas with an concurrent overproduction of aldosterone or cortisol or no concurrent hormone production, or patients diagnosed with adrenocortical carcinoma * For healthy volunteers inclusion criteria included no known diseases, no ongoing medication and no known adrenal anomalies. Exclusion Criteria for patients and healthy volunteers: * pregnancy, age below 18, claustrophobia

What they're measuring

Evaluate safety of up to two administrations of [18F]CETO in up to 15 patients in comparison with 5 healthy controls.

Timeframe: Up to 1 day after the [18F]CETO PET/CT for each patient

Trial details

NCT IDNCT05361083

SponsorUppsala University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-01

View on ClinicalTrials.gov More Primary Aldosteronism Due to Aldosterone Producing Adenoma trials